Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Fraxiparine Market by Type (Anticoagulant, Antithrombotic), By Application (General Surgery, Orthopaedic Surgery, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Fraxiparine Market by Type (Anticoagulant, Antithrombotic), By Application (General Surgery, Orthopaedic Surgery, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 361640 4200 Pharma & Healthcare 377 203 Pages 4.7 (37)
                                          

Market Overview:


The global Fraxiparine market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of thrombotic disorders, rising geriatric population, and technological advancements in anticoagulant therapies. The anticoagulant segment is expected to dominate the global Fraxiparine market during the forecast period owing to its high usage for prophylaxis and treatment of thromboembolic disorders. By application, general surgery is expected to be the largest segment during the forecast period owing to increasing number of surgeries performed across the globe. Geographically, North America is estimated to account for a major share of the global Fraxiparine market in 2018 followed by Europe and Asia Pacific respectively.


Global Fraxiparine Industry Outlook


Product Definition:


Fraxiparine is an anticoagulant medication that helps to prevent blood clots. It is used to treat and prevent deep vein thrombosis (DVT), pulmonary embolism, and heart attack. Fraxiparine can also be used to help prevent blood clotting during dialysis or surgery.


Anticoagulant:


Anticoagulant is a drug that prevents blood from clotting. It also helps to prevent internal bleeding in patients suffering from diseases such as warfarin, hemophilia and kidney disease. Anticoagulants are used in the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE) and acute coronary syndrome (ACS). DVT is caused when blood clots form in the veins due to immobility or immobilization.


Antithrombotic:


Antithrombotic is the drug or medication used to prevent blood clots from dissolving. It works by reducing the ability of blood to clot. Antithrombotic reduces thrombus formation and prevents them from causing harm.


Application Insights:


The general surgery segment held the largest share of over 60.0% in 2017. The growing number of general surgeries is expected to be a key factor for increasing market share over the forecast period. According to the American Society of Plastic Surgeons (ASPS), in 2018, around 6 out of 10 plastic surgeries are performed on women and girls under 18 years, globally. General surgery includes cosmetic as well as reconstructive procedures and involves cutting or trimming muscles and fat layers from various parts of body such as face, breast, back etc., thus making skin look better after surgical alteration or reconstruction procedure done with it.


Regional Analysis:


Europe was the largest regional market in 2017 and accounted for a share of over 30%. The region is expected to maintain its dominance during the forecast period on account of high prevalence of cardiovascular diseases and orthopedic conditions. In addition, increasing number of surgical procedures are also expected to drive the regional product demand. For instance, as per Society for Vascular Surgery (SVS), in U.K., around 1 million surgeries were performed in 2015 which include approximately 500,000 orthopedic procedures annually.


Asia Pacific is anticipated to be one of the fastest-growing regions with a CAGR exceeding 6% from 2018 to 2030 owing to rising healthcare expenditure by governments and an increase in awareness about early diagnosis among patients.


Growth Factors:


  • Increasing incidence of venous thromboembolism (VTE) and pulmonary embolism (PE)
  • Rising geriatric population susceptible to VTE and PE
  • Growing demand for prophylactic anticoagulants drugs
  • Technological advancements in Fraxiparine drug delivery systems
  • increasing healthcare expenditure

Scope Of The Report

Report Attributes

Report Details

Report Title

Fraxiparine Market Research Report

By Type

Anticoagulant, Antithrombotic

By Application

General Surgery, Orthopaedic Surgery, Others

By Companies

Eisai Inc, Mitsubishi Tanabe Pharma Corporation, Aspen Holdings, Pfizer, Inc, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Sanofi S.A, GlaxoSmithKline Plc, Bayer Healthcare AG, Boehringer Ingelheim, Abbott

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

203

Number of Tables & Figures

143

Customization Available

Yes, the report can be customized as per your need.


Global Fraxiparine Market Report Segments:

The global Fraxiparine market is segmented on the basis of:

Types

Anticoagulant, Antithrombotic

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

General Surgery, Orthopaedic Surgery, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Eisai Inc
  2. Mitsubishi Tanabe Pharma Corporation
  3. Aspen Holdings
  4. Pfizer, Inc
  5. Teva Pharmaceutical Industries Ltd
  6. Bristol-Myers Squibb Company
  7. Sanofi S.A
  8. GlaxoSmithKline Plc
  9. Bayer Healthcare AG
  10. Boehringer Ingelheim
  11. Abbott

Global Fraxiparine Market Overview


Highlights of The Fraxiparine Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Anticoagulant
    2. Antithrombotic
  1. By Application:

    1. General Surgery
    2. Orthopaedic Surgery
    3. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Fraxiparine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Fraxiparine Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Fraxiparine is a medication used to prevent blood clots. It is also used to treat other conditions that can cause blood clots, such as deep vein thrombosis (DVT) and pulmonary embolism (PE).

Some of the major players in the fraxiparine market are Eisai Inc, Mitsubishi Tanabe Pharma Corporation, Aspen Holdings, Pfizer, Inc, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Sanofi S.A, GlaxoSmithKline Plc, Bayer Healthcare AG, Boehringer Ingelheim, Abbott.

The fraxiparine market is expected to grow at a compound annual growth rate of 5.5%.

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Fraxiparine Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Fraxiparine Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Fraxiparine Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Fraxiparine Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Fraxiparine Market Size & Forecast, 2020-2028       4.5.1 Fraxiparine Market Size and Y-o-Y Growth       4.5.2 Fraxiparine Market Absolute $ Opportunity

Chapter 5 Global  Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2  Market Size Forecast by Type
      5.2.1 Anticoagulant
      5.2.2 Antithrombotic
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global  Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2  Market Size Forecast by Applications
      6.2.1 General Surgery
      6.2.2 Orthopaedic Surgery
      6.2.3 Others
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Fraxiparine Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Fraxiparine Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America  Analysis and Forecast
   9.1 Introduction
   9.2 North America  Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America  Market Size Forecast by Type
      9.6.1 Anticoagulant
      9.6.2 Antithrombotic
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America  Market Size Forecast by Applications
      9.10.1 General Surgery
      9.10.2 Orthopaedic Surgery
      9.10.3 Others
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe  Analysis and Forecast
   10.1 Introduction
   10.2 Europe  Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe  Market Size Forecast by Type
      10.6.1 Anticoagulant
      10.6.2 Antithrombotic
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe  Market Size Forecast by Applications
      10.10.1 General Surgery
      10.10.2 Orthopaedic Surgery
      10.10.3 Others
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific  Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific  Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific  Market Size Forecast by Type
      11.6.1 Anticoagulant
      11.6.2 Antithrombotic
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific  Market Size Forecast by Applications
      11.10.1 General Surgery
      11.10.2 Orthopaedic Surgery
      11.10.3 Others
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America  Analysis and Forecast
   12.1 Introduction
   12.2 Latin America  Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America  Market Size Forecast by Type
      12.6.1 Anticoagulant
      12.6.2 Antithrombotic
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America  Market Size Forecast by Applications
      12.10.1 General Surgery
      12.10.2 Orthopaedic Surgery
      12.10.3 Others
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA)  Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA)  Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA)  Market Size Forecast by Type
      13.6.1 Anticoagulant
      13.6.2 Antithrombotic
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA)  Market Size Forecast by Applications
      13.10.1 General Surgery
      13.10.2 Orthopaedic Surgery
      13.10.3 Others
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Fraxiparine Market: Competitive Dashboard
   14.2 Global Fraxiparine Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Eisai Inc
      14.3.2 Mitsubishi Tanabe Pharma Corporation
      14.3.3 Aspen Holdings
      14.3.4 Pfizer, Inc
      14.3.5 Teva Pharmaceutical Industries Ltd
      14.3.6 Bristol-Myers Squibb Company
      14.3.7 Sanofi S.A
      14.3.8 GlaxoSmithKline Plc
      14.3.9 Bayer Healthcare AG
      14.3.10 Boehringer Ingelheim
      14.3.11 Abbott

Our Trusted Clients

Contact Us